Indoco Remedies is currently trading at Rs. 340.00, up by 2.55 points or 0.76% from its previous closing of Rs. 337.45 on the BSE.
The scrip opened at Rs. 349.40 and has touched a high and low of Rs. 349.40 and Rs. 331.45 respectively. So far 2316 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 416.95 on 01-Jan-2024 and a 52 week low of Rs. 307.00 on 26-Apr-2023.
Last one week high and low of the scrip stood at Rs. 351.45 and Rs. 331.00 respectively. The current market cap of the company is Rs. 3069.53 crore.
The promoters holding in the company stood at 58.74%, while Institutions and Non-Institutions held 21.25% and 20.00% respectively.
Indoco Remedies has received an approval to purchase land (which was previously held by the Company on leasehold rights) admeasuring 2,860.75 square meters situated at Mahal Industrial Estate, Taluka Andheri, District Mumbai Suburban from an unrelated third-party seller ‘Saldanha Realty and Infrastructure LLP’ for the expansion plans of the Company. Accordingly, the Company executed the Indenture of Conveyance for the purchase of the aforesaid land. The Committee of Executive Directors at its meeting held on March 12, 2024 has approved the same.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1820.75 |
| Dr. Reddys Lab | 1270.95 |
| Cipla | 1333.55 |
| Zydus Lifesciences | 911.85 |
| Lupin | 2343.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: